UK markets closed

NVO Jan 2025 100.000 put

OPR - OPR Delayed price. Currency in USD
Add to watchlist
3.4000-0.2200 (-6.08%)
At close: 01:58PM EDT
Full screen
Previous close3.6200
Open3.4500
Bid3.3500
Ask3.5500
Strike100.00
Expiry date2025-01-17
Day's range3.3600 - 3.4500
Contract rangeN/A
Volume16
Open interest1.58k
  • Reuters

    Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says

    Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company's revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes and autoinjectors. Novo Nordisk's popular obesity drug Wegovy and Eli Lilly's in demand Zepbound are GLP-1 drugs. Siemssen said he expects sales related to GLP-1 medicines to surpass 100 million euros this year and to reach at least 350 million euros ($379 million) within the next three years, based on actual contracts and orders.

  • Zacks

    2 Top Biotech Buyout Candidates

    The resurgence of biotech stocks in recent months marks a promising trend for investors, fueled by a favorable market condition. Strategist Andrew Rocco divulges two biotech stocks with innovative drug pipelines that offer investors the potential to cash in on lucrative buyout opportunities

  • Zacks

    Pharma Stock Roundup: ABBV & NVO's New M&As, FDA Nod to JNJ & MRK PAH Drugs

    While AbbVie (ABBV) is set to buy Landos Biopharma, Novo Nordisk (NVO) is set to acquire Cardior Pharmaceuticals. FDA approves J&J's (JNJ) and Merck's (MRK) PAH drugs.